Urokinase plasminogen activator (Baker IDI Heart & Diabetes Institute/University of Melbourne)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameUrokinase plasminogen activator (Baker IDI Heart & Diabetes Institute/University of Melbourne)

Drug Alias NameGlycoprotein IIb/IIIa stimulator (Baker IDI Heart & Diabetes Institute/University of Melbourne)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionIntegrin alpha-IIb/beta-3 stimulantsUrokinase plasminogen activator inhibitors

TargetsIntegrin alpha-IIb/beta-3Urokinase plasminogen activator

Therapy Area/IndicationsMyocardial InfarctionStroke

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New Zealand

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBaker Idi Heart And Diabetes Institute Holdings Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBaker Idi Heart And Diabetes Institute Holdings Ltd University Of Melbourne

Active IndicationsN/A

Inactive IndicationsMyocardial InfarctionStroke

Other Information

ATC CodeN/A